 Anosheh Afghahi
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2025 | 2456 | 1.550 |
Why?
| | Triple Negative Breast Neoplasms | 4 | 2018 | 216 | 1.270 |
Why?
| | BRCA2 Protein | 4 | 2024 | 67 | 0.890 |
Why?
| | BRCA1 Protein | 4 | 2024 | 81 | 0.890 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.660 |
Why?
| | Sexual Health | 1 | 2020 | 66 | 0.590 |
Why?
| | Cancer Survivors | 2 | 2022 | 327 | 0.580 |
Why?
| | Lymphocyte Count | 1 | 2018 | 164 | 0.540 |
Why?
| | Genetic Testing | 2 | 2017 | 482 | 0.510 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1322 | 0.490 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 61 | 0.440 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 163 | 0.430 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 183 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1141 | 0.400 |
Why?
| | Genomics | 2 | 2016 | 836 | 0.390 |
Why?
| | Germ-Line Mutation | 3 | 2019 | 175 | 0.370 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 434 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2365 | 0.340 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1786 | 0.290 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2197 | 0.260 |
Why?
| | Genes, BRCA1 | 2 | 2017 | 45 | 0.250 |
Why?
| | SEER Program | 2 | 2018 | 224 | 0.240 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 132 | 0.230 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1465 | 0.230 |
Why?
| | Eligibility Determination | 1 | 2025 | 68 | 0.220 |
Why?
| | Middle Aged | 14 | 2025 | 35928 | 0.190 |
Why?
| | Oligopeptides | 1 | 2025 | 269 | 0.190 |
Why?
| | Amyloidosis | 2 | 2013 | 44 | 0.190 |
Why?
| | Carcinoma, Renal Cell | 1 | 2025 | 234 | 0.180 |
Why?
| | Female | 20 | 2025 | 78376 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2022 | 44 | 0.180 |
Why?
| | Quality of Life | 3 | 2025 | 3192 | 0.180 |
Why?
| | Aged | 9 | 2025 | 25947 | 0.170 |
Why?
| | Multiple Myeloma | 1 | 2025 | 304 | 0.170 |
Why?
| | Prophylactic Mastectomy | 1 | 2021 | 10 | 0.170 |
Why?
| | Humans | 23 | 2025 | 144957 | 0.170 |
Why?
| | Chemoprevention | 1 | 2021 | 90 | 0.160 |
Why?
| | Kidney Neoplasms | 1 | 2025 | 412 | 0.160 |
Why?
| | Mutation | 4 | 2024 | 4099 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 489 | 0.160 |
Why?
| | Resistance Training | 1 | 2022 | 182 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1054 | 0.150 |
Why?
| | Neoplasms | 1 | 2015 | 2884 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 586 | 0.140 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 463 | 0.140 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 53 | 0.140 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2018 | 49 | 0.140 |
Why?
| | Carcinoma, Lobular | 1 | 2018 | 56 | 0.140 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2018 | 82 | 0.130 |
Why?
| | Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2017 | 2 | 0.130 |
Why?
| | Penetrance | 1 | 2017 | 30 | 0.130 |
Why?
| | Genes, BRCA2 | 1 | 2017 | 33 | 0.130 |
Why?
| | Adult | 9 | 2025 | 40506 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 154 | 0.120 |
Why?
| | Platinum | 1 | 2017 | 50 | 0.120 |
Why?
| | Carboplatin | 1 | 2017 | 160 | 0.120 |
Why?
| | California | 1 | 2018 | 475 | 0.120 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 260 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1358 | 0.120 |
Why?
| | Mortality | 1 | 2018 | 376 | 0.110 |
Why?
| | Imatinib Mesylate | 1 | 2015 | 77 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 940 | 0.110 |
Why?
| | Trastuzumab | 1 | 2015 | 118 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1325 | 0.110 |
Why?
| | Neoplasm Grading | 1 | 2015 | 309 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 323 | 0.110 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 127 | 0.100 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 509 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 359 | 0.100 |
Why?
| | Prognosis | 2 | 2023 | 4293 | 0.100 |
Why?
| | Melphalan | 1 | 2013 | 43 | 0.100 |
Why?
| | Immunoglobulin Light Chains | 1 | 2013 | 51 | 0.100 |
Why?
| | Thalidomide | 1 | 2013 | 43 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1958 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 647 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 388 | 0.090 |
Why?
| | Laryngeal Diseases | 1 | 2012 | 31 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 883 | 0.080 |
Why?
| | Dexamethasone | 1 | 2013 | 372 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8279 | 0.080 |
Why?
| | Immunotherapy | 1 | 2015 | 657 | 0.080 |
Why?
| | Macrophages | 1 | 2018 | 1511 | 0.080 |
Why?
| | Prevalence | 1 | 2017 | 2836 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 350 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.070 |
Why?
| | Registries | 1 | 2018 | 2385 | 0.070 |
Why?
| | Melanoma | 1 | 2015 | 761 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1472 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2015 | 847 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1177 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3676 | 0.060 |
Why?
| | Biomarkers | 1 | 2018 | 4275 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6053 | 0.060 |
Why?
| | Survival Rate | 2 | 2025 | 2092 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 42 | 0.050 |
Why?
| | Kidney Function Tests | 1 | 2025 | 157 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 185 | 0.050 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 38 | 0.050 |
Why?
| | Creatinine | 1 | 2025 | 506 | 0.050 |
Why?
| | Peptide YY | 1 | 2022 | 25 | 0.050 |
Why?
| | Ghrelin | 1 | 2022 | 39 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 55 | 0.050 |
Why?
| | Risk Factors | 1 | 2017 | 10792 | 0.050 |
Why?
| | Homologous Recombination | 1 | 2022 | 36 | 0.050 |
Why?
| | Breast | 1 | 2023 | 159 | 0.050 |
Why?
| | Appetite | 1 | 2022 | 69 | 0.050 |
Why?
| | Phthalazines | 1 | 2022 | 64 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2642 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2023 | 421 | 0.040 |
Why?
| | Body Image | 1 | 2022 | 97 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 760 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 601 | 0.040 |
Why?
| | Mammography | 1 | 2021 | 166 | 0.040 |
Why?
| | Energy Intake | 1 | 2022 | 500 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2019 | 55 | 0.040 |
Why?
| | Health Education | 1 | 2022 | 358 | 0.040 |
Why?
| | Young Adult | 1 | 2015 | 14126 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2018 | 75 | 0.030 |
Why?
| | Receptors, CCR5 | 1 | 2018 | 60 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2022 | 492 | 0.030 |
Why?
| | Aminopyridines | 1 | 2018 | 127 | 0.030 |
Why?
| | Purines | 1 | 2018 | 187 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11695 | 0.030 |
Why?
| | Benzimidazoles | 1 | 2018 | 190 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2021 | 17101 | 0.030 |
Why?
| | Mastectomy | 1 | 2018 | 162 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 688 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2018 | 356 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1385 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 381 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 695 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 457 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1253 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 605 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 965 | 0.020 |
Why?
| | Male | 4 | 2025 | 72406 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 970 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3608 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2012 | 117 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1048 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3550 | 0.020 |
Why?
| | Metastrongyloidea | 1 | 1969 | 1 | 0.020 |
Why?
| | Mollusca | 1 | 1969 | 6 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1077 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3869 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1495 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1890 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 5965 | 0.010 |
Why?
| | Mice | 1 | 2018 | 18365 | 0.010 |
Why?
| | Animals | 2 | 2018 | 38109 | 0.010 |
Why?
| | Parasitic Diseases, Animal | 1 | 1969 | 6 | 0.000 |
Why?
| | Snails | 1 | 1969 | 37 | 0.000 |
Why?
| | Dog Diseases | 1 | 1969 | 70 | 0.000 |
Why?
| | Ecology | 1 | 1969 | 121 | 0.000 |
Why?
| | Dogs | 1 | 1969 | 438 | 0.000 |
Why?
| | Aging | 1 | 1969 | 1966 | 0.000 |
Why?
|
|
Afghahi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|